A Phase 3 Trial of MM120 for Generalized Anxiety Disorder
Do you struggle with anxiety? You are not alone.
We are doing research for a new investigational treatment option to see if it is effective in improving anxiety. If you suffer from anxiety, you may be eligible to participate.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating MM120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment.
Initial Eligibility Criteria:
- 18 - 74 years old
- Experiencing Anxiety
- Willing to use a highly effective method of contraception
- Willing to stop all medication affecting your mood